Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;4(5):963-6.
doi: 10.2147/ndt.s3201.

The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study

Sibel Cakir  1 , Isin Baral Kulaksizoglu
Affiliations

The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study

Sibel Cakir et al. Neuropsychiatr Dis Treat. 2008 Oct.

Abstract

Agitation is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacotherapy. We aimed to determine the effectiveness and safety of mirtazapine in treatment of agitated patients with Alzheimer's disease (AD). The consecutive patients with AD who have significant agitation were assigned to a 12-week open-label, prospective study. Patients received mirtazapine 15-30 mg/day. The changes in Cohen-Mansfield Agitation Inventory-Short form (CMAI-SF) scores were primary outcome measurement. The change in Clinical Global Impression-Severity scale (CGI-S) scores and tolerability-safety profile were the secondary efficacy variables. Thirteen of 16 (81.25%) patients completed the study. There was a significant reduction in CMAI-SF and CGI-S between the pre- and post-treatment with mirtzapaine (p < 0.001). The mean baseline score was 26.54 ( +/- 5.4) and mean reduction was 10.6 ( +/- 7.5) in CMAI-SF. There was no significant side effect and cognitive deterioration. The results of this open-label pilot study suggest that mirtazapine may be an effective choice for treatment of agitated patients with AD.

Keywords: Alzheimer’s disease; agitation; mirtazapine; open-label; safety; treatment.

PubMed Disclaimer

References

    1. Ballard CG, Margallo-Lana M, Fossey J, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry. 2001;62:631–6. - PubMed
    1. Ballard C, WaIte J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;25:CD003476. - PMC - PubMed
    1. Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722–7. - PubMed
    1. Cohen-Mansfield J. Assessment of agitation. Int Psychogeriatr. 1996;8:233–45. - PubMed
    1. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia – a preliminary study. Arch Gerontol Geriatr. 2000;31:65–76. - PubMed

LinkOut - more resources